Most Read Articles
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

ARBs, ACEIs useful for treating COVID-19 patients with pre-existing hypertension

23 May 2020

Angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) show superiority over other blood pressure (BP)-lowering medications in terms of reducing high-sensitivity C-reactive protein (hs-CRP) and procalcitonin levels in COVID-19 patients with pre-existing hypertension, as shown in a recent study.

The retrospective analysis included 126 hypertensive COVID-19 patients (median age, 66 years; 49.2 percent male) who received treatment with ARBs/ACEIs (n=43) or non-ARBs/ACEIs (n=83) and 125 matched nonhypertensive COVID-19 controls (median age, 66 years; 48.8 percent male). Researchers also reviewed the medication history of 1,942 hypertensive patients (non-COVID-19) hospitalized prior to the outbreak for external comparison.

Compared with controls, hypertensive patients had higher levels of systolic and diastolic blood pressure (125/75 vs 120/70 mm Hg; p=0.031 and p=0.004, respectively) and were more likely to have diabetes (30.2 percent vs 13.6 percent; p=0.002) and cardiopathy (18.3 percent vs 9.6 percent; p=0.048).

Of note, the frequency of ARBs/ACEIs usage was similar in hypertensive patients with and without COVID-19 (34.1 percent vs 35.4 percent; p=0.767).

In the group of COVID-19 patients with hypertension, BP did not significantly differ between those who received ARBs/ACEIs and those on non-ARBs/ACEIs. However, treatment with ARBs/ACEIs was associated with significantly lower concentrations of hs-CRP (p=0.049) and procalcitonin (p=0.008), as well as numerically fewer critically ill patients (9.3 percent vs 22.9 percent; p=0.061) and a lower number of deaths (4.7 percent vs 13.3 percent; p=0.216).

The present data support the use of ARBs/ACEIs over other antihypertensive drugs in the treatment of COVID-19 patients with hypertension, researchers said. Large prospective studies are needed to validate the results and to explore the mechanisms by which ARBs/ACEIs regulate the inflammatory response.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.